S

Sanofi

Global pharma company; vaccines and R&D

Rheumatology Key Account Specialist

Full-TimeUpdated on 10/23/2026Deadline 11/20/26
$125.3k - $180.9k
Mid
Bachelor's
Remote in USA
RemoteUS Remote; travel up to 80% throughout the nation to the home office and meetings/conventions. Applicants must be U.S. or Puerto Rico residents.
Sales & Account ManagementField Sales

About the job

Requirements
  • At least 3 years of specialty sales experience within pharmaceutical or biotechnology.
  • A bachelor's degree is required.
  • A successful track record of performance in physician/customer-facing and strategic roles is required.
  • Experience with pull-through and total-office calls is required.
  • Ability to operate and thrive in an ambiguous environment is required.
  • Effective communication and change agility skills are required.
  • Strong business acumen and project management skills are required.
  • Ability to travel up to 80% of the time throughout the nation, to the home office, and to meetings and conventions as required.
Responsibilities
  • Engage rheumatology customers within the assigned geographic territory and deliver clinically focused messages to introduce, launch, grow brand share and revenue, and consistently deliver product goals.
  • Execute strategies and tactics within accounts in the rheumatology therapeutic area to generate product utilization.
  • Develop strong working relationships with rheumatology experts and other rheumatology specialists in the assigned geography, as well as nurses, office staff, other important healthcare personnel, and key patient advocacy support groups as directed.
  • Coordinate with other rheumatology cross-functional team members, especially overlapping Thought Leader Liaisons in the territory, to ensure optimal account success.
  • Conduct presentations and fluently convey clinical information to healthcare professionals, including institutional physicians in large academic centers, hospitals, and large group practices, in a professional, compliant, ethical, and effective manner.
  • Demonstrate deep marketplace, therapeutic, product, and disease expertise grounded in rigorous scientific principles and data, including mechanism of action, indications, efficacy, and safety; provide key market insights and field feedback to the home office.
  • Coordinate and communicate with field-based and home-office personnel to proactively address customer needs, market dynamics, and trends, and develop strategies supporting brand and corporate objectives in the assigned geography.
  • Participate in and help lead initiatives supporting sales success, such as industry-related congresses and local and regional meetings.
  • Provide site-level in-service training as required by accounts, in person, digitally, or virtually according to account needs.
  • Plan, organize, and sponsor local promotional speaker programs and activities.
  • Effectively execute short- and long-term strategic plans.
  • Maximize the budget allocated to the geographic territory to support strategies and tactics developed to generate and grow the business.
  • Drive results by identifying key opportunities and developing strategic plans to enhance and grow territory business.
  • Own business opportunities within the geographic area, coordinating and calling on large group practices, integrated delivery networks, and other key targets to drive product results.
  • Establish relationships with key leaders in the assigned territory, with the primary objective of driving industry-leading customer value.
  • Lead cross-functional teams in implementing Sanofi US programs and brand-specific strategies in the assigned geography.
  • Allocate resources in accordance with business opportunities.
  • Train and effectively launch Kevzara for the polymyalgia rheumatica indication as part of the Kevzara sales team.
Desired Qualifications
  • At least 2 years of rheumatology sales experience is highly preferred.
  • Launch experience is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...